NCT07114861

Phase 1/Phase 2Interventional

Trials that are a combination of phases 1 and 2.

Timeline

Start date: Oct 22, 2025
Primary completion: Sep 22, 2028
Completion date: Oct 22, 2028
First posted: Aug 11, 2025
Last posted: Aug 11, 2025
Enrollment: 30
Arms / groups: 2 / —
Source: AACT · ctgov ingestion

Drugs studied

irinotecan
fluorouracil
Filgrastim
leucovorin
ondansetron
oxaliplatin
aprepitant
dexamethasone
kn510
kn713

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.